Encouraging High-Pressure Slurry Ablation Test Results at Myriad's Copper Mountain Uranium Project

Myriad Uranium announced an initial 2026 testing campaign with DISA Uranium using samples from the company. The program is evaluating whether DISA's high-pressure slurry ablation technology can efficiently concentrate uranium and improve uranium recovery from the concentrated material fraction. No recovery-rate, grade, cost, or other quantitative test results were disclosed in the article.

Analysis

The relevant valuation question is not whether laboratory concentration works, but whether it lowers all-in recovery cost and capital intensity at mine scale. For a pre-production uranium developer, even a material uplift in concentrate grade has little NAV impact until management discloses independently assayed recovery rates, reagent/water/energy intensity, throughput, and a scalable flowsheet; absent these, the announcement should not support a rerating comparable to an economic study or permitting milestone. The likely near-term effect is promotional liquidity rather than durable institutional demand, particularly given the limited depth typical of OTC/CSE-listed resource equities.

If the process ultimately reduces haulage, grinding, or leach-plant feed volumes, the second-order beneficiary could be DISA rather than Myriad: a validated technology platform can be deployed across multiple low-grade uranium deposits, creating option value beyond one orebody. Conversely, conventional ISR-focused uranium developers such as Ur-Energy (URG), Uranium Energy (UEC), and enCore Energy (EU) would not be directly disadvantaged; their investment case is driven by permitting, wellfield productivity, and operating execution rather than hard-rock beneficiation. Over 6-18 months, a credible pilot-scale result could improve financing optionality for Myriad, but it could also expose a funding gap if scale-up requires a specialized processing plant before resource conversion or feasibility work is complete.

Contrarian view: the market often capitalizes apparent recovery improvements as though they are additive to recoverable pounds, when metallurgical gains can be offset by lower throughput, fines handling, abrasion, water use, or difficult downstream leaching. The catalyst path over the next 1-3 months is therefore disclosure quality, not another promotional test result. A thesis of technology-enabled cost reduction is falsified by pilot results showing no material reduction in projected $/lb uranium recovery cost, poor repeatability across mineralized zones, or an inability to produce saleable uranium concentrate at commercially relevant scale.

Key Decisions for Investors

• No immediate position in MYRUF/CSE:M: treat the release as an observation event, not a fundamental catalyst, until independently verified mass pull, uranium recovery, feed grade, operating cost and throughput data are published. Any exposure should be sized as venture-capital-like optionality because liquidity and financing risk dominate.
• Set a 1-3 month diligence alert for a pilot program, third-party metallurgical report, or updated economic study that quantifies an all-in $/lb improvement. Consider a small long only if projected recovery cost falls materially versus the prior baseline and the company identifies funded scale-up; exit on equity financing at a steep discount without a corresponding technical de-risking event.
• For liquid uranium exposure, prefer established producers/developers such as UEC, URG, or the URA ETF rather than using Myriad as a proxy for uranium-price upside. This isolates the macro uranium thesis from unproven process-scale-up and microcap liquidity risk.
• Monitor DISA commercialization evidence as the higher-convexity second-order angle: signed paid pilots with multiple orebody types, independently validated recoveries, or royalty/equipment economics would be more investable evidence than a single issuer-sponsored test campaign.